81
Participants
Start Date
August 10, 2021
Primary Completion Date
November 10, 2022
Study Completion Date
March 10, 2023
BNT162b2 vaccine (Pfizer/BioNTech)
30 microgram dose
mRNA-1273 vaccine (Moderna)
100 microgram dose
Johns Hopkins Hospital, Baltimore
Collaborators (1)
PPD Development, LP
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH